Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
BRIEF—Amgen dismisses obesity drug safety concern; investors unsure
US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide (maridebart cafraglutide,
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.
STAT16h
AbbVie’s stumble, Amgen’s tumble and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
FierceBiotech2d
Hidden data on obesity prospect wipe $12B off Amgen market cap
Amgen’s share price fell 7% in the wake of Brayer’s note, wiping $12 billion off the biotech’s market cap. However, ...
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...
Amgen posts higher profit, obesity data on track for late this year
Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...
What Analysts Are Saying About Amgen Stock
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
stocknews13d
3 Biotechnology Stocks With Promising Pipelines
With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.
Citi initiates coverage on 5 new biotech stocks
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...
The Motley Fool28d
Is Amgen Stock a Buy?
Here's what you need to know. Amgen is recognized as a biotech pioneer with a long history of groundbreaking discoveries. From developing Epogen in the 1980s as one of the first recombinant DNA ...
Employee Benefits4d
Amgen receives menopause-friendly employer accreditation
Biotechnology firm Amgen has been awarded menopause-friendly employer accreditation as part of its aim to ensure all of its ...